This project integrates ongoing P50-supported research progress in the Ransohoff lab, and related work from the lab of our collaborator Claudia Lucchinetti, now serving as co-PI. The P50 competing renewal represents a substantial extension of work ongoing in the Pis'labs. The emphasis is on cortical demyelination and meningeal inflammation early in MS, as well as leukocyte trafficking to the cortex and subarachnoid space. P50 research will be leveraged through Dr. Lucchinetti's R01NS49577, on which Dr. Ransohoff is co-PI. During analysis of biopsy material from eariy MS cases in the Lucchinetti lab, cortical demyelination (CDM) proved to be a common finding and collaboration with the Ransohoff group disclosed frequent association with meningeal inflammation. Notably, biopsies were performed to examine white matter changes on MRI, and the findings of CDM with meningeal inflammafion were unexpected. These findings however correlate well with MRI reports demonstrafing diffuse and focal cortical damage in eariy MS. Taken in the context of other recent results, our data in early MS suggest the novel hypothesis that meningeal inflammation and CDM promote white matter lesions during the MS disease process. This hypothesis will be addressed in Specific Aims 1 and 2 and will include detailed phenotyping of leukocytes within CDM lesions, including analysis of chemokine receptors. Importanfiy, recent studies in animal models identified specific chemokine receptors as candidate trafficking determinants for meninges and cortex.
In Aim 3, we will use a novel flow-based in-vitro blood-brain barrier (BBB) model to define which chemokine receptors are essential for transmigrafion, enabling the identificafion of potenfial therapeufic targets for selective suppression of meningeal inflammafion and cortical demyelinafion, and to refine our interpretation of research results obtained during performance of Aims 1 and 2.
|Trapp, Bruce D; Vignos, Megan; Dudman, Jessica et al. (2018) Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 17:870-884|
|Lowe, Mark J; Sakaie, Ken E; Beall, Erik B et al. (2016) Modern Methods for Interrogating the Human Connectome. J Int Neuropsychol Soc 22:105-19|
|Paz Soldán, M Mateo; Novotna, Martina; Abou Zeid, Nuhad et al. (2015) Relapses and disability accumulation in progressive multiple sclerosis. Neurology 84:81-8|
|Takeshita, Yukio; Obermeier, Birgit; Cotleur, Anne et al. (2014) An in vitro blood-brain barrier model combining shear stress and endothelial cell/astrocyte co-culture. J Neurosci Methods 232:165-72|
|Criste, Gerson; Trapp, Bruce; Dutta, Ranjan (2014) Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol 122:101-13|
|Dutta, Ranjan; Trapp, Bruce D (2014) Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 27:271-8|
|Beall, Erik B; Lowe, Mark J (2014) SimPACE: generating simulated motion corrupted BOLD data with synthetic-navigated acquisition for the development and evaluation of SLOMOCO: a new, highly effective slicewise motion correction. Neuroimage 101:21-34|
|Tutuncu, Melih; Tang, Junger; Zeid, Nuhad Abou et al. (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19:188-98|
|Rudick, Richard A; Fisher, Elizabeth (2013) Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes. Mult Scler 19:1003-4|
|Dutta, Ranjan; Chomyk, Anthony M; Chang, Ansi et al. (2013) Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 73:637-45|
Showing the most recent 10 out of 34 publications